New generation biologics for the treatment of psoriasis and psoriatic arthritis. State of the art and considerations about the risk of infection

被引：18
作者：
Ceccarelli, Manuela [1 ,2 ]
Rullo, Emmanuele Venanzi [3 ]
Berretta, Massimiliano [3 ]
Cacopardo, Bruno [1 ]
Pellicano, Giovanni Francesco [4 ]
Nunnari, Giuseppe [3 ]
Guarneri, Claudio [2 ]
机构：
[1] Univ Catania, Dept Clin & Expt Med, Unit Infect Dis, Catania, Italy
[2] Univ Messina, Dept Biomed & Dent Sci & Morpho Funct Imaging, Messina, Italy
[3] Univ Messina, Dept Clin & Expt Med, Unit Infect Dis, Messina, Italy
[4] Univ Messina, Dept Adult & Childhood Human Pathol Gaetano Barre, Messina, Italy
来源：
DERMATOLOGIC THERAPY | 2021年 / 34卷 / 01期
关键词：
infection; interleukin‐ 17; 23; psoriasis; psoriatic arthritis; SARS‐ CoV‐ 2; SERIOUS INFECTIONS; PLAQUE PSORIASIS; CLOSTRIDIUM-DIFFICILE; SAFETY; MULTICENTER; COVID-19; CHILDREN; RISANKIZUMAB; GUSELKUMAB; EFFICACY;
D O I：
10.1111/dth.14660
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
Psoriasis is a chronic immune-mediated disease characterized by inflammation of skin (psoriasis) or joints (psoriatic arthritis) or both, resulting from a dysregulation in particular of the T helper (Th)17 functions. There is no available cure for psoriasis, and a life-long treatment is needed to control signs and symptoms. Research interest is high around the newest biological drugs approved for the treatment of moderate to severe psoriasis and psoriatic arthritis, and especially drugs blocking the IL-23/IL-17 axis. Our aim is to review the new biological drugs for the treatment of psoriasis and their adverse effects, focusing on the risk of infections.
引用
收藏
页数：7
相关论文
共 55 条
  • [21] The Incidence and Predictors of Infection in Psoriasis and Psoriatic Arthritis: Results from Longitudinal Observational Cohorts
    Haddad, Amir
    Li, Suzanne
    Thavaneswaran, Arane
    Cook, Richard J.
    Chandran, Vinod
    Gladman, Dafna D.
    [J]. JOURNAL OF RHEUMATOLOGY, 2016, 43 (02) : 362 - 366
  • [22] Discovery of the IL-23/IL-17 Signaling Pathway and the Treatment of Psoriasis
    Hawkes, Jason E.
    Yan, Bernice Y.
    Chan, Tom C.
    Krueger, James G.
    [J]. JOURNAL OF IMMUNOLOGY, 2018, 201 (06) : 1605 - 1613
  • [23] Serious infections in hospitalized patients with psoriasis in the United States
    Hsu, Derek Y.
    Gordon, Kenneth
    Silverberg, Jonathan I.
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2016, 75 (02) : 287 - 296
  • [24] Clostridium difficile: A European perspective
    Jones, A. M.
    Kuijper, E. J.
    Wilcox, M. H.
    [J]. JOURNAL OF INFECTION, 2013, 66 (02) : 115 - 128
  • [25] Pharmacokinetics of Tildrakizumab (MK-3222), an Anti-IL-23 Monoclonal Antibody, After Intravenous or Subcutaneous Administration in Healthy Subjects
    Khalilieh, Sauzanne
    Hodsman, Peter
    Xu, Christine
    Tzontcheva, Anjela
    Glasgow, Shirley
    Montgomery, Diana
    [J]. BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2018, 123 (03) : 294 - 300
  • [26] Long-term safety profile of ixekizumab in patients with moderate-to-severe plaque psoriasis: an integrated analysis from 11 clinical trials
    Langley, R. G.
    Kimball, A. B.
    Nakagawa, H.
    Xu, W.
    Pangallo, B.
    Osuntokun, O. O.
    Agada, N.
    Reich, K.
    [J]. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2019, 33 (02) : 333 - 339
  • [27] Should biologics for psoriasis be interrupted in the era of COVID-19?
    Lebwohl, Mark
    Rivera-Oyola, Ryan
    Murrell, Dedee F.
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2020, 82 (05) : 1217 - 1218
  • [28] Adalimumab in severe plaque psoriasis of childhood: A multi-center, retrospective real-life study up to 52 weeks observation
    Lernia, Vito D.
    Bianchi, Luca
    Guerriero, Cristina
    Stingeni, Luca
    Gisondi, Paolo
    Filoni, Angela
    Guarneri, Claudio
    Fortina, Anna Belloni
    Lasagni, Claudia
    Simonetti, Oriana
    Neri, Iria
    Zangrilli, Arianna
    Moretta, Gaia
    Hansel, Katharina
    Casanova, Dahiana M.
    Girolomoni, Giampiero
    Cannavo, Serafinella P.
    Bonamonte, Domenico
    [J]. DERMATOLOGIC THERAPY, 2019, 32 (06)
  • [29] Comparative risk of serious infections among real-world users of biologics for psoriasis or psoriatic arthritis
    Li, Xintong
    Andersen, Kathleen M.
    Chang, Hsien-Yen
    Curtis, Jeffrey R.
    Alexander, G. Caleb
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 (02) : 285 - 291
  • [30] Spotlight on risankizumab and its potential in the treatment of plaque psoriasis: evidence to date
    Machado, Alvaro
    Torres, Tiago
    [J]. PSORIASIS-TARGETS AND THERAPY, 2018, 8 : 83 - 92
123456